Gossamer Bio (GOSS) Total Non-Current Liabilities (2018)
Gossamer Bio (GOSS) posted Total Non-Current Liabilities of $20.4 million for Q4 2018.
Powered by 
Analysis
Gossamer Bio (GOSS) Total Non-Current Liabilities (2018) Analysis & Trends
Gossamer Bio has reported Total Non-Current Liabilities for 1 years, with the latest figure at $20.4 million in Q4 2018.
- On a quarterly basis, Total Non-Current Liabilities changed N/A year-over-year to $20.4 million in Q4 2018; TTM through Dec 2018 was $20.4 million, a N/A change from a year earlier, with the FY2018 full-year figure at $20.4 million, changed N/A from the prior year.
- Total Non-Current Liabilities was $20.4 million for Q4 2018 at Gossamer Bio.
- The five-year high for Total Non-Current Liabilities was $20.4 million in Q4 2018, with the low at $20.4 million in Q4 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 105.99 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 106.45 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 16.16 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 48.34 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 100.86 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 32.04 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | 1.53 Bn |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 1.40 Bn |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | 607.80 Mn |
| 10 | Gossamer Bio | 57.60 Mn | 576,568.19 | - | - |